TABLE 3.

Changes in MG-ADL, QMG, MGC scores, and individual muscle scores for bulbar muscles, limb muscles, neck muscles, respiratory muscles, and ocular muscles in 14 gMG patients before treatment and at 1, 3, 6, and 12 months after ofatumumab treatment.

Variable	Baseline	1 Month	3 Months	6 Months	12 Months	P-value
	n = 14	n = 14	n = 14	n = 14	n = 14
MG-ADL	13.00 (6.75, 15.25)	5.00 (2.00, 9.00)	3.50 (1.75, 5.25)	2.00 (0.00, 3.75)	1.00 (0.00, 2.25)	<0.001 a
QMG	16.50 (10.75, 21.25)	8.00 (4.75, 12.00)	5.50 (2.75, 8.00)	3.00 (1.75, 6.50)	2.00 (1.00, 4.25)	<0.001 a
MGC	12.00 (4.75, 21.50)	5.00 (3.00, 12.25)	4.00 (1.50, 7.25)	3.00 (0.00, 7.00)	2.00 (1.00, 6.00)	<0.001 a
Bulbar muscles	5.00 (3.00, 5.50)	1.50 (0.00, 2.25)	1.00 (0.00, 2.00)	1.00 (0.00, 1.00)	0.50 (0.00, 1.00)	<0.001 a
Limb muscles	4.00 (3.75, 5.25)	2.00 (1.00, 3.00)	1.00 (0.00, 1.00)	0.00 (0.00, 1.25)	0.00 (0.00, 1.00)	<0.001 a
Neck muscles	3.00 (2.00, 5.25)	1.00 (0.00, 2.25)	1.00 (0.00, 1.00)	1.00 (0.00, 1.25)	0.50 (0.00, 1.00)	<0.001 a
Respiratory muscles	2.00 (1.00, 3.00)	2.00 (1.00, 2.00)	1.00 (0.75, 2.00)	1.00 (0.00, 1.00)	0.00 (0.00, 1.00)	<0.001 a
Ocular muscles	2.50 (1.00, 3.25)	2.00 (1.00, 2.00)	1.00 (1.00, 2.00)	1.00 (1.00, 1.00)	1.00 (0.00, 1.00)	0.007 a
CD19+ B cells	12.11 (8.46, 20.09)	0.16 (0.03, 0.58)	0.00 (0.00, 0.31)	0.10 (0.03, 0.47)	1.15 (0.09, 5.09)	<0.001 a
Total T cells	69.47 ± 13.60	74.64 ± 12.80	75.18 ± 15.11	78.10 ± 16.81	75.32 ± 15.16	0.640b

MG-ADL, myasthenia gravis activities of daily living; QMG, quantitative myasthenia gravis score; MGC, Myasthenia Gravis Composite. a: Friedman test; b: repeated-measures ANOVA. All tests are two-sided with α = 0.05; p < 0.001 is reported as “<0.001”. Asterisks indicate comparisons versus baseline (Bonferroni-corrected). Statistically significant results (p < 0.05) are shown in bold.